['diabetes']
['dapagliflozin', 'dapagliflozin placebo']

        Inclusion Criteria:

          -  Subjects must have type 2 diabetes with inadequate glycemic control, defined as HbA1c
             ≥ 7.5% and ≤ 11.0% obtained at screening visit

          -  Subjects must be taking a stable mean dose of ≥ 20 IU injectable insulin daily for at
             least 8 weeks prior to enrollment

        Inclusion criteria for randomization:

        HbA1c ≥ 7.5 and ≤ 10.5% at Day -14

        Exclusion Criteria:

          -  Treatment with more than two oral antidiabetic (OAD) agents within 6 weeks of
             Enrollment

          -  History of diabetic ketoacidosis of hyperosmolar nonketotic coma

          -  Clinically diagnosed Type 1 diabetes mellitus

          -  Congestive heart failure defined as New York Heart Association (NYHA) stage III and IV

          -  Severe uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 180 mmHg
             and/or diastolic blood pressure (DBP) ≥ 110 mmHg

          -  History of unstable or rapidly progressing renal disease

          -  History of severe hepatobiliary disease

          -  Mallingancy within 5 years of the screening/enrollment visit
      